

intact *BAX* genes from NSAID-mediated apoptosis. This prediction was confirmed by introducing a Bcl-X<sub>L</sub> expression vector into HCT116 cells and assessing colony formation after treatment with NSAIDs (Fig. 4D).

It was not expected that deletion of a single gene could so profoundly affect cell death in a human cancer cell. Previous experiments have shown that NSAIDs induce heterogeneous changes in human tumor cells, including growth arrest, apoptosis, and necrosis (21). Despite this heterogeneity, we found that most colorectal cancer cell lines exhibited markedly similar changes in BAX:Bcl-X<sub>L</sub> ratios, whereas the others died through mechanisms that were independent of BAX:Bcl-X<sub>L</sub>. Furthermore, the importance of *BAX* was rigorously demonstrated in HCT116 cells through three different approaches for generating cells with disrupted *BAX* genes. In addition to their implications for understanding basic determinants of drug responsiveness in human cancer cells, these results may have important clinical implications. It is currently believed that chemoprevention offers the best hope for nonsurgical management of patients with hereditary predispositions to colorectal cancer. The most common form of such predisposition is hereditary nonpolyposis colorectal cancer, which is caused by defects in mismatch repair (22). Our results suggest that such tumors may easily develop resistance to NSAIDs through an inherent instability in the mononucleotide tract in *BAX*. By analogy with the successful strategy used to combat the highly mutable retroviruses that cause acquired immunodeficiency syndrome (23), it may therefore be important to consider combinations of chemopreventive drugs, rather than single agents, in such patients.

*Note added in proof:* It has recently been shown that tumor cells without *BAX* undergo less apoptosis when xenografted in mice (27).

References and Notes

1. A. Gross, J. M. McDonnell, S. J. Korsmeyer, *Genes Dev.* **13**, 1899 (1999).
2. D. R. Green, J. C. Reed, *Science* **281**, 1309 (1998).
3. Reviewed in M. E. McCurrach, T. M. Connor, C. M. Knudson, S. J. Korsmeyer, S. W. Lowe, *Proc. Natl. Acad. Sci. U.S.A.* **94**, 2345 (1997).
4. Reviewed in T. G. Huang, S. M. Ip, W. S. Yeung, H. Y. Ngan, *Eur. J. Cancer* **36**, 249 (2000).
5. C. M. Knudson, K. S. K. Tung, W. G. Tourtellotte, G. A. J. Brown, S. J. Korsmeyer, *Science* **270**, 96 (1995).
6. D. M. Pritchard, C. S. Potten, S. J. Korsmeyer, S. Roberts, J. A. Hickman, *Oncogene* **18**, 7287 (1999).
7. C. M. Coopersmith, J. I. Gordon, *Oncogene* **15**, 131 (1997).
8. T. Schmidt et al., *Cell Death Differ.* **6**, 873 (1999).
9. A. Gross, J. Jockel, M. C. Wei, S. J. Korsmeyer, *EMBO J.* **17**, 3878 (1998).
10. J. Lewis et al., *Nature Med.* **5**, 832 (1999).
11. F. Bunz et al., *J. Clin. Invest.* **104**, 263 (1999).
12. C. Williams, R. L. Shattuck-Brandt, R. N. DuBois, *Ann. N.Y. Acad. Sci.* **889**, 72 (1999).
13. T. C. He, T. A. Chan, B. Vogelstein, K. W. Kinzler, *Cell* **99**, 335 (1999).
14. Y. Yamamoto, M. J. Yin, K. M. Lin, R. B. Gaynor, *J. Biol. Chem.* **274**, 27307 (1999).

15. Y. Ionov, M. A. Peinado, S. Malkhosyan, D. Shibata, M. Perucho, *Nature* **363**, 558 (1993).
16. N. Rampino et al., *Science* **275**, 967 (1997).
17. HCT116 subclones were obtained by single-cell dilution. Genomic DNA from individual clones was isolated in 96-well plates. To measure the length of the *BAX* G-tract, we labeled polymerase chain reaction (PCR) primers with [<sup>32</sup>P]adenosine 5'-triphosphate using T4 kinase and used them to amplify *BAX* genomic DNA fragments. The primers used for amplification were 5'-CAGTTCGCCCCGATGCGC-3' and 5'-AGGAGTGACACCCCGTCTG-3'.
18. Supplemental Web material is available at *Science* Online at [www.sciencemag.org/feature/data/1055633.shl](http://www.sciencemag.org/feature/data/1055633.shl).
19. An HCT116 clone heterozygous for *BAX* was transfected with the targeting construct (Fig. 2A) using Lipofectamine (Life Technologies, Rockville, MD). Twenty-four hours after transfection, cells were plated at clonal density in 96-well plates in media containing hygromycin (0.1 mg/ml). Hygromycin-resistant clones were expanded and screened for targeting events with PCR. Two PCR-positive clones were recovered from ~5000 hygromycin-resistant clones. Homologous recombination at the *BAX* locus was verified by genomic Southern blotting with the probe indicated in Fig. 2A, sequencing of the G<sub>8</sub>-tract and surrounding nucleotides of the remaining *BAX* allele, and analysis of *BAX* protein expression. Details of the targeting construct and the primers used for PCR are available from the authors upon request.
20. M. G. Vander Heiden, C. B. Thompson, *Nature Cell Biol.* **1**, E209 (1999).
21. M. L. Smith, G. Hawcroft, M. A. Hull, *Eur. J. Cancer* **36**, 664 (2000).
22. H. T. Lynch, A. de La Chapelle, *J. Med. Genet.* **36**, 801 (1999).
23. S. C. Johnson, J. G. Gerber, *Adv. Intern. Med.* **45**, 1 (2000).
24. F. Bunz et al., *Science* **282**, 1497 (1998).
25. T. Waldman, C. Lengauer, K. W. Kinzler, B. Vogelstein, *Nature* **381**, 713 (1996).
26. HCT116 cells were transfected with a Bcl-X<sub>L</sub> expression plasmid (Invitrogen) or a control plasmid with no insert (pcDNA3.1/GS, Invitrogen). Twenty-four hours after transfection, cells were treated with indomethacin (500 μM) for 48 hours. About 10<sup>7</sup> indomethacin-treated cells and 10<sup>5</sup> untreated cells were inoculated in separate T25 flasks and treated with Zeocin (0.5 mg/ml, Invitrogen) for 3 days to select for transfected cells. Colonies were visualized by crystal violet staining 7 to 10 days later.
27. Y. Ionov et al. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 10872 (2000).
28. We thank L. Zawal, I. Rhee, E. Carson-Walter, S. Zhou, T. Chan, and F. Bunz for experimental advice; C. Lengauer and L. Meszler for help with cell imaging; and J. Flook for assistance with fluorescence-activated cell sorting. Supported by the Clayton Fund and by NIH grants CA 43460, CA 57345, CA 62924, GM 41690, and GM07309. B.H.P. is a recipient of the Howard Hughes postdoctoral fellowship for physicians. K.W.K. received research funding from Genzyme Molecular Oncology (Genzyme). B.V. and K.W.K. are consultants to Genzyme. The university and researchers (L.Z., B.V., and K.W.K.) own Genzyme stock, which is subject to certain restrictions under university policy. The terms of these arrangements are being managed by the university in accordance with its conflict of interest policies.

18 May 2000; accepted 11 September 2000

## A PEST-Like Sequence in Listeriolysin O Essential for *Listeria monocytogenes* Pathogenicity

Amy L. Decatur<sup>1</sup> and Daniel A. Portnoy<sup>1,2\*</sup>

Establishment and maintenance of an intracellular niche are critical to the success of an intracellular pathogen. Here, the pore-forming protein listeriolysin O (LLO), secreted by *Listeria monocytogenes*, was shown to contain a PEST-like sequence (P, Pro; E, Glu; S, Ser; T, Thr) that is essential for the virulence and intracellular compartmentalization of this pathogen. Mutants lacking the PEST-like sequence entered the host cytosol but subsequently permeabilized and killed the host cell. LLO lacking the PEST-like sequence accumulated in the host-cell cytosol, suggesting that this sequence targets LLO for degradation. Transfer of the sequence to perfringolysin O transformed this toxic cytolysin into a nontoxic derivative that facilitated intracellular growth.

Intracellular pathogens reside in specific cellular compartments, e.g., a modified phagosome (*Mycobacterium tuberculosis*) (1), the Golgi apparatus (*Chlamydia trachomatis*) (2), or the cytosol (*L. monocytogenes*) (3). How pathogens establish and maintain these intracellular niches is the essence of patho-

genesis. Although we know little of the molecular mechanisms by which intracellular pathogens achieve compartmentalization, one emerging theme is that pathogens exploit the existing cellular machinery of the host (4).

The secreted pore-forming protein LLO of the facultative intracellular bacterial pathogen *L. monocytogenes* is an essential virulence determinant that allows the bacterium to escape from the host vacuole and reach the host cytosol (5). Although LLO is produced by bacteria in both the cytosol and the vacuole, LLO activity is restricted to the vacuolar

<sup>1</sup>Department of Molecular and Cell Biology, <sup>2</sup>Division of Infectious Diseases, School of Public Health, University of California, Berkeley, CA 94720, USA.

\*To whom correspondence should be addressed. E-mail: portnoy@uclink4.berkeley.edu

## REPORTS

compartment (6, 7). In contrast, *L. monocytogenes* that are engineered to produce a related pore-forming protein, perfringolysin O (PFO), from the extracellular pathogen *Clostridium perfringens*, escape from the vacuole but subsequently lyse the plasma membrane and kill the host cell (8). Thus, LLO is unique, not in its ability to mediate vacuolar escape, but in its lack of host-cell toxicity.

To identify features of LLO that might mediate its compartment-specific activity, we compared the LLO and PFO primary sequences (9). LLO and PFO have 43% sequence identity and 70% sequence similarity. However, LLO contains a 27-amino acid sequence in its NH<sub>2</sub>-terminus that is absent from PFO (Fig. 1A). Within this unique region is a 19-amino acid PEST-like sequence (10). PEST sequences are thought to target eukaryotic proteins for phosphorylation and/or degradation (10, 11) and, more generally, may represent sites of protein-protein interaction. We considered the possibility that the PEST-like sequence of LLO may target this potentially toxic bacterial protein for degradation, and thus inactivation, specifically within the host-cell cytosol.

To determine if the PEST-like sequence of LLO is important for *L. monocytogenes* pathogenicity, we generated a 26-amino acid in-frame deletion that removed the PEST-like sequence (Fig. 1A) and introduced the resulting allele onto the *L. monocytogenes* chromosome in place of the wild-type allele (strain DP-L4042) (12). In vitro, the mutant protein (LLOΔ26) exhibited full hemolytic activity (Table 1). However, in a murine model of infection, strain DP-L4042 was four orders of magnitude less virulent than wild-type bacteria (Table 1).

To understand why the mutant bacteria were less virulent in vivo, we examined the interaction of these bacteria with macrophages in vitro. Subsequent to internalization, the mutant bacteria escaped from host phagosomes with an efficiency similar to that of wild-type bacteria (Table 1). However, during the first 6 hours of intracellular growth, wild-type bacteria doubled approximately five times, whereas bacteria producing either LLOΔ26 or PFO showed a 1000-fold decrease in colony forming units (Fig. 1B). In contrast, bacteria that did not produce any cytolysin remained trapped, but viable, in phagosomes of the nonbactericidal J774 cells (Fig. 1B). Because the antibiotic gentamicin was added to the tissue culture media 30 min after bacterial internalization, these results suggest that, like PFO, LLOΔ26 permeabilized the host plasma membrane and consequently allowed gentamicin access to the intracellular bacteria.


Upon visualization of infected macrophages, it was clear that bacteria producing LLOΔ26 were toxic to their host cells in a

manner that was inversely correlated to the presence of gentamicin. Thus, in the absence of gentamicin, virtually all macrophages infected with the mutant bacteria were dead by 6 hours after infection, as indicated by their dark condensed nuclei and loss of membrane integrity (Fig. 2C). In contrast, infections carried out in the presence of gentamicin revealed that, although some macrophages infected with bacteria producing LLOΔ26 were dead (~5 to 10%), most macrophages infected with the mutant bacteria appeared viable. However, these viable macrophages contained only 4 to 12 bacteria at time points when macrophages infected with wild-type bacteria contained ~100 bacteria (Fig. 2, B and A, respectively). Given that many

mammalian cells are able to patch holes in their plasma membrane (13), we speculate that most infected macrophages recovered when gentamicin was present to kill the LLOΔ26-producing bacteria.

To measure cytotoxicity directly, we monitored the release of a host cytosolic enzyme, lactate dehydrogenase (LDH), into the tissue culture medium (14). To favor host-cell lysis over rapid bacterial death and host-cell repair, we performed the infections for this assay in the absence of gentamicin. Infection of J774 cells with LLOΔ26-producing bacteria resulted in 90% of the maximal LDH release, compared to only 2% for wild-type bacteria. Thus, LLOΔ26 was inappropriately active within the host-cell cytosol and conse-

**Fig. 1.** (A) LLO, but not PFO, contains a PEST-like sequence in its NH<sub>2</sub>-terminus. In (A), a partial sequence comparison between LLO (top) and PFO (bottom) is shown, starting at the mature NH<sub>2</sub>-terminus of each protein (26). Identical residues are indicated by vertical lines; similar residues are indicated by two dots. The PEST-like sequence of LLO scored a 4.72 in the PESTfind algorithm (10) and is shown in bold. The 26 amino acids removed in LLOΔ26 are underlined. The three consensus MAPK sites are boxed. (B to E) Growth of *L. monocytogenes* strains in J774 macrophages. Monolayers of J774 cells were grown on glass coverslips (27) and infected with bacteria producing the indicated cytolysin at an effective MOI of 1 (B) or 1:10 (C to E). At the specified times after infection, monolayers were lysed, and the number of bacteria per coverslip was determined in triplicate. In each case, gentamicin (50 μg/ml) was added 30 min after bacterial internalization.



**Table 1.** Properties of bacteria producing either wild-type (WT) or mutant LLO proteins. Hemolytic units are expressed as the reciprocal of the dilution of bacterial culture supernatant required for 50% lysis of a 0.5% sheep red blood cell suspension as described (8). Escape from primary phagosomes of murine bone marrow-derived macrophages was determined by using indirect immunofluorescence to count the percentage of bacteria decorated with actin filaments 90 min after infection (8). Association with host actin indicates that the bacterium has reached the cytosol. Strain DP-L2161 contains a complete deletion of the LLO gene (8). LD<sub>50</sub>, 50% lethal doses (25).

Strain	Cytolysin synthesized	Hemolytic units		Escape from phagosome (%)	LD <sub>50</sub>
		pH 5.5	pH 7.4		
10403S	WT LLO	1061	114	59 ± 6	2 × 10 <sup>4</sup>
DP-L4042	LLOΔ26	1514	243	55 ± 4	2 × 10 <sup>8</sup>
DP-L4048	LLO <sub>S44A,S48A,T51A</sub>	1330	151	54 ± 4	3 × 10 <sup>6</sup>
DP-L2161	No cytolysin	0	0	0	2 × 10 <sup>9</sup>

## REPORTS

quently acted on the cytoplasmic membrane.

The observed toxicity of LLO $\Delta$ 26 may reflect the fact that the 26-amino acid sequence missing from this mutant protein targets wild-type LLO for degradation and, thus, inactivation within the host cytosol. If so, removal of this signal should lead to the accumulation of LLO within the host cytosol. Detection of intracellular LLO $\Delta$ 26, however, was technically difficult because bacteria synthesizing this protein caused host-cell lysis as early as 2 hours after infection, a time at which there were too few bacteria for recovery and detection of most bacterial proteins. Thus, we introduced a second site mutation in the COOH-terminal domain of LLO [Gly<sup>486</sup>  $\rightarrow$  Asp<sup>486</sup> (G486D)] based on an analogous substitution in PFO (15) that rendered LLO much less active (>100-fold), yet still allowed bacteria to escape, albeit less efficiently, from host phagosomes. Bacteria synthesizing LLO $\Delta$ 26<sub>G486D</sub> were much less toxic to their host cells and were able to replicate intracellularly (Fig. 1C). As a control, we also introduced the G486D substitution into an otherwise wild-type LLO molecule. We immunoprecipitated LLO from infected J774 macrophages that had been metabolically labeled at 5 hours after infection. Two species of intracellular wild-type LLO were detected: full-length mature LLO of 58 kD (as confirmed by comigration with in vitro labeled LLO) and a truncated form of 55 kD, which may represent a degradation product (7). We observed the same two species with LLO<sub>G486D</sub>. In contrast, LLO $\Delta$ 26<sub>G486D</sub> was present inside host cells at substantially higher levels than either wild-type LLO or LLO<sub>G486D</sub> (Fig. 3B). In addition, we did not detect any degradation products of


LLO $\Delta$ 26<sub>G486D</sub>. These data do not distinguish between increased intracellular synthesis or decreased intracellular degradation (16). However, we did not observe an increased accumulation of LLO $\Delta$ 26 when the bacteria were grown in broth culture (Fig. 3A), suggesting that the mutant protein was synthesized and secreted normally outside of the host environment (17).

PEST sequences often contain internal phosphorylation sites, and phosphorylation at these sites often precedes protein degradation (11). LLO contains several potential phosphorylation sites within the 26-amino acid region described above, including three consensus mitogen-activated protein kinase (MAPK) sites (PXS/TP) (18) (Fig. 1). To determine whether these sites play a role in inactivating cytosolic LLO, we generated a mutant LLO protein in which all three of the potential phosphate acceptor residues were changed to a residue (Ala) that cannot accept phosphate. In vitro, LLO<sub>S44A,S48A,T51A</sub> [S44A, Ser<sup>44</sup>  $\rightarrow$  Ala<sup>44</sup>; S48A, Ser<sup>48</sup>  $\rightarrow$  Ala<sup>48</sup>; T51A, Thr<sup>51</sup>  $\rightarrow$  Ala<sup>51</sup>] exhibited hemolytic activity similar to that of the wild-type protein (Table 1), and bacteria synthesizing LLO<sub>S44A,S48A,T51A</sub> escaped from the primary vacuole with an efficiency similar to that of wild-type bacteria (Table 1). However, in support of our hypothesis, bacteria producing LLO<sub>S44A,S48A,T51A</sub> were toxic to macrophages in vitro (Fig. 1D) and were 100-fold less virulent in vivo (Table 1). Moreover, like LLO $\Delta$ 26<sub>G486D</sub>, LLO<sub>G486D</sub> lacking the three putative MAPK sites (LLO<sub>S44A,S48A,T51A,G486D</sub>) accumulated to higher levels within infected macrophages than either wild-type LLO or LLO<sub>G486D</sub> (19).


If the PEST-like sequence inactivates

LLO within the host cytosol, transfer of this sequence to the related cytolysin PFO should render PFO less toxic to host cells. To test this idea, we generated a protein chimera in which the leader peptide and the first 35 residues of mature LLO (which contain the PEST-like sequence) were fused in-frame to the PFO protein (PFO+PEST) (20). To control for possible differences in secretion efficiency between the leader peptides of LLO and PFO, we generated a second protein chimera in which the LLO leader peptide alone was fused in-frame to PFO (PFO-No PEST) (20). We tested *L. monocytogenes* strains carrying either the PFO+PEST or the PFO-No PEST allele in place of the wild-type LLO allele for the ability to grow inside macrophages. Bacteria producing the PFO+PEST protein were able to replicate intracellularly and were much less toxic to their host macrophages than bacteria producing the PFO-No PEST protein (Fig. 2, D through F). This rescue was only partial, however, in that bacteria producing PFO+PEST did not grow as well as wild-type bacteria and were still toxic at later time points in the infection (Fig. 1E). Nonetheless, when we quantitated cytotoxicity by monitoring the release of host LDH (14), bacteria producing PFO+PEST were much less toxic than those producing the PFO-No PEST control protein (9 versus 97% maximal LDH release, respectively) and only slightly more toxic than wild-type bacteria (2% maximal LDH release).

The PEST-like sequence of LLO is essential for *L. monocytogenes* to establish a pro-



**Fig. 2.** Light micrographs of J774 macrophages at 6 hours after infection with *L. monocytogenes*. Each panel depicts a macrophage(s) infected with bacteria producing either (A) wild-type LLO, (B) and (C) LLO $\Delta$ 26, (D) PFO+PEST, or (E and F) PFO-No PEST at an effective MOI of 1:10. In (C) and (F), macrophages were infected in the absence of gentamicin; in all other panels, gentamicin (50  $\mu$ g/ml) was added 30 min after bacterial internalization. Scale bar, 10  $\mu$ m.



**Fig. 3.** LLO lacking the PEST-like sequence accumulates to high levels inside, but not outside, of host cells. (A) Western blot showing the relative levels of wild-type and LLO $\Delta$ 26 protein found in the supernatant of bacterial cultures after 5 hours of growth in Luria-Bertani broth. Secreted proteins were isolated as described (8) and subjected to Western blot analysis with polyclonal antibodies raised against LLO. Each lane represents supernatant from equivalent numbers of bacteria. (B) Autoradiograph showing the relative levels of LLO<sub>G486D</sub> and LLO $\Delta$ 26<sub>G486D</sub> recovered from infected macrophages. Bacterial proteins were metabolically labeled with [<sup>35</sup>S]methionine during growth in J774 cells (7) at 5 hours after infection. LLO was immunoprecipitated as described (7) and subjected to SDS-polyacrylamide gel electrophoresis. Each lane represents a single J774 monolayer ( $\sim 4 \times 10^6$  cells) that contained  $7 \times 10^7$  DP-L4044 (LLO<sub>G486D</sub>) or  $7.7 \times 10^7$  DP-L4045 (LLO $\Delta$ 26<sub>G486D</sub>) bacteria. The arrow indicates full-length LLO<sub>G486D</sub>, the solid arrowhead indicates truncated LLO<sub>G486D</sub>, and the open arrowhead indicates full-length LLO $\Delta$ 26<sub>G486D</sub>.

ductive infection in vivo. Our data suggest that this sequence restricts LLO activity to the host-cell vacuole, thereby preserving the intracellular niche of *L. monocytogenes*. Perhaps rapid host-cell lysis by LLOΔ26 exposes the normally intracellular bacteria to extracellular host defenses such as humoral immunity and bactericidal phagocytes.

LLO and PFO are members of a large family of pore-forming proteins (21), but LLO is the only one to be produced by an intracellular pathogen. Our data suggest that the addition of a simple sequence tag to a toxic pore-forming protein can convert it into a molecule specialized for intracellular use. Moreover, because intracellular pathogens often use host-cell machinery for their own purposes, *L. monocytogenes* may achieve the critical balance between efficient escape from a vacuole and avoidance of host-cell damage by incorporating a eukaryotic protein degradation signal into a potentially toxic bacterial virulence factor.

References and Notes

1. D. L. Clemens, *Trends Microbiol.* **4**, 113 (1996).
2. T. Hackstadt, M. A. Scidmore, D. D. Rockey, *Proc. Natl. Acad. Sci. U.S.A.* **92**, 4877 (1995).
3. L. G. Tilney, D. A. Portnoy, *J. Cell Biol.* **109**, 1597 (1989).
4. B. B. Finlay, P. Cossart, *Science* **276**, 718 (1997).
5. D. A. Portnoy, T. Chakraborty, W. Goebel, P. Cossart, *Infect. Immun.* **60**, 1263 (1992).
6. M. S. Villanueva, A. J. Sijts, E. G. Pamer, *J. Immunol.* **155**, 5227 (1995).
7. M. A. Moors, B. Levitt, P. Youngman, D. A. Portnoy, *Infect. Immun.* **67**, 131 (1999).
8. S. Jones, D. A. Portnoy, *Infect. Immun.* **62**, 5608 (1994).
9. The two sequences can be found by SWISS-PROT accession numbers P13128 (LLO) and P19995 (PFO).
10. S. Rogers, R. Wells, M. Rechsteiner, *Science* **234**, 364 (1986).
11. M. Rechsteiner, S. W. Rogers, *Trends Biochem. Sci.* **21**, 267 (1996).
12. Mutant alleles of the LLO gene (*hly*) were generated by oligonucleotide-directed mutagenesis using splice overlap extension (SOE) polymerase chain reaction (PCR) (22) and introduced onto the *L. monocytogenes* chromosome by allelic exchange (23). In all cases, the starting template for PCR was chromosomal DNA isolated from wild-type *L. monocytogenes* (strain 10403S). For each resulting strain, DP-L4042 (LLOΔ26), DP-L4044 (LLO<sub>G486D</sub>), DP-L4045 (LLOΔ26<sub>G486D</sub>), and DP-L4048 (LLO<sub>S44A,S48A,T51A</sub>), the LLO allele was confirmed by sequencing.
13. P. L. McNeil, R. A. Steinhardt, *J. Cell Biol.* **137**, 1 (1997).
14. J774 macrophages were grown in a 96-well plate and infected (or mock infected) with the appropriate bacterial strain at a multiplicity of infection (MOI) resulting in approximately one to two bacteria/macrophage. Five hours after infection, supernatant from each well was removed and assayed for LDH activity by using the CytoTox 96 kit (Promega, Madison, WI). Percent cytotoxicity = 100 × [(experimental LDH release) - (spontaneous LDH release)] / [(maximum LDH release) - (spontaneous LDH release)]. The numbers reported were calculated with the mean LDH release from eight wells of a single experiment and are representative of two independent experiments.
15. S. Jones, K. Preiter, D. A. Portnoy, *Mol. Microbiol.* **21**, 1219 (1996).
16. For technical reasons, we were unable to measure half-lives for wild-type LLO or LLO<sub>G486D</sub>.
17. LLO has an acidic pH optimum that has been hypothesized to compartmentalize intracellular hemolytic activity by exploiting the difference in pH between the vacuole (acidic) and cytosol (neutral) of the host

- (8). In vitro, LLOΔ26 was two times as active at neutral pH as the wild-type protein (Table 1). Thus, it is possible that increased activity at neutral pH was responsible for the toxic phenotype of bacteria producing LLOΔ26. However, bacteria producing a mutant LLO protein exhibiting hemolytic activity similar to that of wild-type LLO at pH 5.5, but 9 to 10 times that at pH 7.4, were not toxic to macrophages (24). Moreover, a second protein mutant in the PEST-like region (LLO<sub>S44A,S48A,T51A</sub>) did not exhibit increased hemolytic activity at pH 7.4 (Table 1), yet bacteria synthesizing this mutant protein were also toxic to host cells. Thus, we think it unlikely that altered pH optimum is the cause of toxicity by LLOΔ26.
18. F. A. Gonzalez, D. L. Raden, R. J. Davis, *J. Biol. Chem.* **266**, 22159 (1991).
19. A. L. Decatur, D. A. Portnoy, data not shown.
20. SOE PCR (22) was used to join the LLO and PFO coding sequences to generate gene fusions *hly1-59:pfo37-500* (PFO+PEST) and *hly1-24:pfo29-500* (PFO-No PEST) using either wild-type *L. monocytogenes* chromosomal DNA (strain 10403S) or pDP2169 plasmid DNA (8) as template. For the PFO+PEST fusion, we chose to fuse the PEST-like sequence of LLO to the 37th residue of PFO because it is at this residue (isoleucine) that PFO resumes strong sequence similarity to LLO (Fig. 1A). For the PFO-No PEST fusion, LLO's signal sequence was fused to full-length mature PFO. The gene fusions were introduced onto the *L. monocytogenes* chromosome by allelic exchange (23), yielding strains DP-L4052

- (PFO+PEST) and DP-L4055 (PFO-No PEST). In each case, the genotype was confirmed by sequencing.
21. J. E. Alouf, C. Geoffroy, in *Sourcebook of Bacterial Protein Toxins*, J. E. Alouf, J. H. Freer, Eds. (Academic Press, London, 1991), pp. 147-186.
22. S. N. Ho, H. D. Hunt, R. M. Horton, J. K. Pullen, L. R. Pease, *Gene* **77**, 51 (1989).
23. N. E. Freitag, in *Gram-Positive Pathogens*, V. A. Fischetti et al., Eds. (ASM Press, Washington, DC, 2000), chap. 51.
24. M. Gedde, D. A. Portnoy, unpublished data.
25. LD<sub>50</sub> values for DP-L4042 and DP-L4048 were determined as described (8), by using groups of four BALB/c mice for each bacterial dilution.
26. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; and Y, Tyr.
27. S. Jones, D. A. Portnoy, *Methods Enzymol.* **236**, 463 (1994).
28. We thank A. Bouwer for the animal studies, M. Gedde and M. O'Riordan for helpful discussions, and M. J. Bosma, V. J. DiRita, and P. A. Levin for critical reading of the manuscript. We also thank P. Cossart for providing monoclonal antibody to LLO. This work was supported by NIH grant AI27655 (D.A.P.) and National Research Service Award postdoctoral fellowship AI0283 (A.L.D.).

19 June 2000; accepted 18 September 2000

## Role of *Bacillus subtilis* SpoIIIE in DNA Transport Across the Mother Cell-Prespore Division Septum

Jonathan Bath,<sup>1</sup> Ling Juan Wu,<sup>2</sup> Jeffery Errington,<sup>2</sup> James C. Wang<sup>1\*</sup>

The SpoIIIE protein of *Bacillus subtilis* is required for chromosome segregation during spore formation. The COOH-terminal cytoplasmic part of SpoIIIE was shown to be a DNA-dependent adenosine triphosphatase (ATPase) capable of tracking along DNA in the presence of ATP, and the NH<sub>2</sub>-terminal part of the protein was found to mediate its localization to the division septum. Thus, during sporulation, SpoIIIE appears to act as a DNA pump that actively moves one of the replicated pair of chromosomes into the prespore. The presence of SpoIIIE homologs in a broad range of bacteria suggests that this mechanism for active transport of DNA may be widespread.

Despite decades of studies, few proteins directly involved in chromosome segregation in bacteria have been identified, and mechanistic information about these proteins is meager. In *Bacillus subtilis*, the newly replicated regions of the chromosome are actively and rapidly separated, but how this movement is achieved is unclear (1-3). Cell division at the onset of spore formation in *B. subtilis* provides an interesting system for studying chro-

mosome movement. Here, an asymmetrically positioned division septum is formed before the completion of chromosome segregation and closes around one of the pair of replicated chromosomes, pinching it into a larger and a smaller lobe. The larger chromosome lobe is then transported from the mother cell into the prespore, presumably through a small pore in the septum. In the absence of a functional SpoIIIE protein, DNA transfer is blocked (4).

During spore formation, SpoIIIE is targeted to the leading edge of the septum. The putative transmembrane domain at the NH<sub>2</sub>-terminal part of the protein appears to play an essential role in this specific localization (5). The strategic location of the protein suggests

<sup>1</sup>Department of Molecular and Cellular Biology, Harvard University, MA 02138, USA. <sup>2</sup>Sir William Dunn School of Pathology, Oxford University, Oxford OX1 3RE, UK.

\*To whom correspondence should be addressed. E-mail: jcwang@fas.harvard.edu